Amplia Therapeutics
Amplia Therapeutics Limited focuses on developing therapies targeting focal adhesion kinase (FAK) inhibitors for the treatment of cancer and fibrosis. The company is positioned within the biotechnology sector, leveraging advanced scientific research to develop clinical candidates aimed at unmet medical needs, potentially offering transformative therapies in oncology and fibrotic diseases.
Short position
Amplia Therapeutics (ASX:ATX) has 0.01% of its shares on issue reported as short positions as of 5 Oct 2026, or about 30,144 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.23% in November 2024. ATX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Amplia Therapeutics (ATX) financials
Results, ratios and statements
Latest result
Year to 31 Mar 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $0M (source: ASX (Markit))vs $0M (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 29 Sep 2026
- NPAT
- −$7.7Mvs −$6.6M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.016vs −$0.021 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aFY
- ASX (Markit)
Key ratios
Year to 31 Mar 2026 (FY); balance sheet at 31 Mar 2026; prices to 9 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- −25.5%
- ROA
- −23.9%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $27.9M
- Net debt / EBITDA
- n/a
- Current ratio
- 19.8×
- Interest cover
- −758.7×
- Cash dividends paid / net profit
- n/a
- Market cap
- $53.9M
- P/E
- n/a
- P/B
- 1.4×
Ratios use the reporting currency (AUD); market cap is in AUD. Sources: Yahoo Finance and ASX (Markit), as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) | $4.4MM (source: ASX (Markit)) | $1.1MM (source: ASX (Markit)) |
| Operating income | −$13.2M | −$10.6M | −$9.0M | −$7.5M |
| EBITDA | −$7.6M | −$6.4M | −$4.3M | −$6.1M |
| EBIT | −$7.7M | −$6.5M | −$4.4M | −$6.2M |
| Interest expense | $17.4K | $55.9K | $78.5K | $53.8K |
| Pretax income | −$7.7M | −$6.6M | −$4.5M | −$6.2M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$7.7M | −$6.6M | −$4.5M | −$6.2M |
| Net interest income | $681.7K | $219.9K | $66.6K | $43.4K |
| EPS basic | −$0.016 | −$0.021 | −$0.022 | −$0.031 |
| EPS diluted | −$0.016 | −$0.021 | −$0.022 | −$0.031 |
| Shares | 513.1M | 388.0M | 203.7M | 203.7M |
- ASX (Markit)
Financial reports
The company's own filings, newest first
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2026via asx_announcements
- Preliminary Final Report and Annual Report YE 31 March 2026Annual Results29 May 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Apr 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results27 Nov 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Oct 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2025via asx_announcements
- Preliminary Final Report and Annual Report YE 31 March 2025Annual Results30 May 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Apr 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2025via asx_announcements
Showing 10 of 79 reports